BlinkLab (ASX: BB1) — Perfil da empresa, notícias e dados financeiros
BlinkLab is a digital healthcare technology company developing mobile diagnostic tools for neurodevelopmental and psychiatric conditions.
BlinkLab
BlinkLab is a digital healthcare technology company developing mobile diagnostic tools for neurodevelopmental and psychiatric conditions. Founded as a spin-off based on technology developed at Princeton University, the company utilizes smartphone-based artificial intelligence and computer vision to deliver objective reflex-based assessments, such as acoustic startle response and prepulse inhibition. Its core platform is designed to assist clinicians in the early screening and diagnosis of autism spectrum disorder and attention deficit hyperactivity disorder. Headquartered in Perth, Australia, the company conducts clinical studies and research collaborations with academic institutions and healthcare providers across Australia, Europe, and the United States.
Resumo
Operações
Produtos e/ou serviços de BlinkLab
- Autism Diagnostic Platform: Smartphone-based digital healthcare tool utilizing computer vision and artificial intelligence to evaluate sensory gating and acoustic startle reflex responses, aiding clinicians in early autism spectrum disorder assessments across clinical and remote patient environments.
- ADHD Assessment Expansion: Clinical testing platform extending smartphone reflex measurements to evaluate attention deficit hyperactivity disorder, collecting neurobehavioral biomarkers across pediatric and adult cohorts to support diagnostic expansion across European and international clinical trial sites.
- Research SaaS Portal: Cloud-based diagnostic dashboard and testing infrastructure providing remote neurobehavioral evaluation tools for academic medical centers and research institutions conducting large-scale studies on neurodevelopmental, psychiatric, and neurological conditions.
- North American Clinical Operations: Clinical validation network partnering with medical centers including Drexel University and Rush University Medical Center, executing clinical trials and gathering empirical dataset evidence to fulfill regulatory submission requirements with health authorities.
- European Clinical Trial Network: Clinical research partnerships and testing programs across the Netherlands and broader Europe, including Erasmus MC and Mental Care Group, evaluating smartphone-based reflex testing for neurodevelopmental and psychiatric diagnostic applications.
- Australian Research Operations: Clinical trial infrastructure and institutional research collaborations across Australia, including Monash University, managing study participant recruitment, local data compliance, and trial execution within domestic healthcare and university hospital networks.
equipe executiva do BlinkLab
- Hendrikus Johannes BoeleCo-Founder, CEO, MD & Director
- Anton Uvarov BioChemCo-Founder, COO & Executive Director
- Cornelis Peter BoeleCo-Founder & CTO
- Sebastiaan K.E KoekkoekCo-Founder & Chief Quality and Regulatory Officer
- Myrthe OttenhoffChief Medical Officer
- Christopher Bryan James AchurchCompany Secretary
Comunicados recentes
O que a BlinkLab (BB1) comunicou ao mercado, do mais recente para o mais antigo.
- BB1 to Present at Simons Foundation and ThinkEquity in NYC
- BB1 to Present at Spark Plus Aussie Equities Day Singapore
- BB1 Granted Foundational U.S. Patent
Principais indicadores financeiros
Resultados divulgados pela BlinkLab, em AUD.
- Cap. de mercado
- 111,1 mi
- Receita (TTM)
- 1,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -8,4 mi | -7,2 mi | |
| 375,6 mil | -5,7 mi | -5,7 mi | |
| 37 mil | -1,7 mi | -1,8 mi | |
| 0 | -675,1 mil | -676,4 mil |